Bank of Japan's Ueda Flags Low Real Interest Rates as Key Factor in Rate Hike Timing 
Dollar Retreats as Strait of Hormuz Reopens, Easing Safe-Haven Demand 
U.S. Crude Oil Exports Surge Toward Record Highs Amid Global Supply Crisis 
Australia's Job Market Holds Firm in March 2026 with Strong Full-Time Hiring 
Japan Eyes Private Credit as Key Pillar in New Financial Strategy 
Uranium Bull Market Gains Momentum Amid Supply Deficits and Geopolitical Tensions 
China's Economy Shows Resilience Amid Global Headwinds in March 
Oil Prices Plunge as Strait of Hormuz Reopens Amid U.S.-Iran Ceasefire Talks 
U.S. Stock Futures Hold Steady After S&P 500 and Nasdaq Hit Record Highs 
U.S. and Philippines to Build 4,000-Acre Tech Hub Under Pax Silica Initiative 
U.S.-Iran Ceasefire Uncertainty Keeps Oil Prices Under Pressure 
Asian Currencies Hold Steady Amid Iran Peace Talks and BOJ Rate Hike Uncertainty 
IMF Warns Middle East War to Deepen Economic Divide Across Latin America and Caribbean 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
China's Economy Surpasses Q1 2026 Growth Forecasts 
Oil Prices Dip as Middle East Peace Hopes Grow Amid Iran-U.S. Talks 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
